.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BX03_Pirenzepine.Pirenzepine .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BX03_Pirenzepine.Pirenzepine| name: | Pirenzepine |
| ATC code: | A02BX03 | route: | oral |
| n-compartments | 1 |
Pirenzepine is a selective muscarinic M1 receptor antagonist used primarily in the past for the treatment of peptic ulcer disease and other gastric acid-related disorders. It reduces gastric acid secretion. It has largely fallen out of use and is no longer widely approved for current clinical use in many countries.
Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.
Bozler, G, & Hammer, R (1980). An international pharmacokinetic study on pirenzepine following a single oral dose. Scandinavian journal of gastroenterology. Supplement 66 27–33. PUBMED:https://pubmed.ncbi.nlm.nih.gov/6941374
Sathirakul, K, et al., & Wise, SD (2003). Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. British journal of clinical pharmacology 56(2) 184–187. DOI:10.1046/j.1365-2125.2003.01857.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12895191
Lane, HY, et al., & Chang, WH (2000). Disposition of olanzapine in Chinese schizophrenic patients. International journal of clinical pharmacology and therapeutics 38(10) 482–485. DOI:10.5414/cpp38482 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11073289